Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. reported that its president and chief business officer, John Fesko, received a grant of 1,774 fully vested restricted stock units (RSUs), each representing one share of common stock. These RSUs were issued as a stock award with no cash price per share.
On the following day, Fesko executed an open-market sale of 707 shares of common stock at $204.1327 per share. According to the footnotes, this sale was carried out to satisfy tax withholding and remittance obligations related to the RSU vesting and was made pursuant to written instructions intended to meet Rule 10b5-1(c) conditions. After these transactions, Fesko directly held 189,199 shares of Natera common stock.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported compensation-related stock activity. He received 1,774 fully vested Restricted Stock Units (RSUs), each representing the right to one share of Natera common stock. The next day, he sold 915 shares of common stock at $204.1327 per share.
The sale was carried out to satisfy tax withholding and remittance obligations arising from the RSU vesting and was made under a written instruction intended to meet the Rule 10b5-1(c) affirmative defense conditions in his March 9, 2026 stock unit agreement. After these transactions, he directly held 150,882 shares of Natera common stock.
Natera, Inc. executive Daniel Rabinowitz, the Secretary and Chief Legal Officer, exercised options to acquire 5,598 shares of common stock at an exercise price of $19.68 per share. These options were fully exercisable.
On the same date, he sold a total of 8,398 shares of Natera common stock in open-market transactions at weighted-average prices disclosed between $193.27 and $198.32 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. After these transactions, he continued to hold 233,285 shares of Natera common stock directly.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of common shares of the issuer. The filing lists multiple recent dispositions by Daniel Rabinowitz, including 19,234 shares for $4,514,958.39 on 01/20/2026 and 1,334 shares for $307,844.51 on 02/03/2026.
Natera, Inc. director and co-founder Jonathan Sheena reported mixed equity activity in Natera stock. On March 2, 2026, he completed open-market sales totaling 3,070 shares of Common Stock at weighted average prices ranging from $198.24 to $202.85 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 7, 2024. Following these sales, his directly held stake reported in this filing was 262,194 shares.
On February 27, 2026, Sheena also received a grant of 2,103 Restricted Stock Units (RSUs), each representing a contingent right to one share of Common Stock. The RSUs vest over four years, with 25% vesting on March 1, 2027 and the rest in 12 equal quarterly installments. The filing also notes indirect holdings in trusts for beneficiaries, for which he disclaims beneficial ownership.
Natera, Inc. director and CEO Steven Leonard Chapman reported both an equity award and share sales. On February 27, 2026, he received 37,401 Restricted Stock Units (RSUs), which vest over four years starting March 1, 2027, with each RSU representing one common share. On March 2, 2026, he sold a total of 3,950 shares of common stock in three open-market transactions at weighted average prices around $199–$201 per share, executed under a pre-established Rule 10b5-1 trading plan adopted December 11, 2023 and amended December 2, 2024. Following these transactions, he directly held 156,607 common shares.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported multiple equity transactions. On March 2, 2026, he exercised stock options for 5,125 shares of common stock at a stated price of $9.5900 per share and received the underlying shares. That same day he sold a total of 3,000 shares of common stock in open‑market transactions in three blocks at weighted average prices of $198.8338, $200.1073, and $200.9679 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 26, 2024, leaving 150,023 shares held directly after the reported sales. On February 27, 2026, he also received a grant of 10,051 restricted stock units, each representing one share of common stock, which vest over four years, with 25% vesting on March 1, 2027 and the rest vesting in 12 equal quarterly installments thereafter.
Rabinowitz Matthew reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. executive chairman Matthew Rabinowitz received an equity award of 29,920 restricted stock units (RSUs). The RSUs were granted on February 27, 2026 at no cash cost and each RSU represents one share of common stock. Vesting begins March 1, 2027, when 25% vests, with the remainder vesting in 12 equal quarterly installments over the following three years.
RABINOWITZ DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, received a grant of 12,272 restricted stock units (RSUs) of common stock on February 27, 2026. These RSUs vest over four years, with 25% vesting on March 1, 2027 and the remainder in 12 equal quarterly installments. Each RSU represents the right to receive one share of Natera common stock, bringing his directly owned total to 236,085 shares after the award.
Fesko John reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. reported that President and Chief Business Officer John Fesko received a grant of 10,051 restricted stock units (RSUs) on common stock. These RSUs vest over four years, with 25% vesting on March 1, 2027 and the rest in 12 equal quarterly installments. After this award, Fesko holds 188,132 shares of common stock directly.